Revolutionary Immunotherapy Approach Achieves Complete Remission in Aggressive Cancers Through Targeted Tumor Injection
For decades,harnessing the power of the immune system to fight cancer – immunotherapy – has held immense promise. Though, realizing that potential has been hampered by meaningful challenges, including systemic toxicity and limited response rates. Now, a groundbreaking study from researchers at Rockefeller university, detailed in a recent publication, unveils a novel immunotherapy strategy utilizing a modified CD40 antibody, 2141-V11, that demonstrates remarkable efficacy and a substantially improved safety profile. This approach,centered around direct tumor injection,has achieved complete remission in a subset of patients with notoriously aggressive and recurring cancers,offering a beacon of hope in the fight against these devastating diseases.
the Challenge with CD40 Activation & A Novel Solution
CD40 is a crucial receptor on immune cells, playing a vital role in activating the immune response against cancer. Antibodies targeting CD40, like V11, have shown promise in preclinical studies. However,systemic administration of these antibodies often leads to widespread immune activation,triggering debilitating and perhaps life-threatening side effects. This is because CD40 receptors are present on numerous non-cancerous cells throughout the body.
The rockefeller team, led by Dr. Michel Ravetch, overcame this hurdle through a clever modification of the V11 antibody. 2141-V11 is engineered to not only bind tightly to CD40 but also to enhance its crosslinking by engaging a specific Fc receptor. This modification dramatically increases the antibody’s potency – a tenfold improvement in its ability to stimulate an antitumor immune response.
Crucially,the researchers shifted the administration strategy from intravenous delivery to direct injection into the tumor itself. This localized approach minimizes systemic exposure,drastically reducing toxicity. “When we did that, we saw only mild toxicity,” explains Dr. Ravetch, highlighting the significant impact of this change.
Phase 1 Trial Results: A Paradigm Shift in Cancer Treatment
The efficacy of 2141-V11 and its targeted delivery method was evaluated in a Phase 1 clinical trial involving 12 patients with advanced, metastatic cancers, including melanoma, renal cell carcinoma, and various types of breast cancer.The primary goal of this initial trial was to determine a safe starting dose and understand the drug’s mechanism of action.
The results were nothing short of remarkable. None of the patients experienced the severe side effects commonly associated with other CD40-targeting therapies. Furthermore, six patients exhibited systemic tumor reduction, with two achieving complete remission – meaning all detectable cancer disappeared.
These complete remissions occurred in patients with melanoma and breast cancer, both cancers known for their aggressive nature and propensity for recurrence. Dr. Ravetch illustrates the impact with a compelling example: “The melanoma patient had dozens of metastatic tumors on her leg and foot, and we injected just one tumor up on her thigh. after multiple injections of that one tumor, all the other tumors disappeared.” A similar phenomenon was observed in the breast cancer patient, with regression of tumors in the skin, liver, and lung following injection into a single skin tumor.
Creating an Immune Fortress Within the tumor
Detailed analysis of tissue samples taken from the tumor sites revealed a profound shift in the tumor microenvironment. The injected tumors transformed into hubs of immune activity,teeming with dendritic cells,T cells,and mature B cells. These immune cells aggregated, forming structures remarkably similar to tertiary lymphoid structures (TLS).
TLS are organized collections of immune cells that develop within non-lymphoid tissues,like tumors. Their presence is strongly correlated with improved prognosis and enhanced response to immunotherapy. As Dr. Jose Osorio explains, “The drug creates an immune microenvironment within the tumor, and essentially replaces the tumor with these tertiary lymphoid structures.”
Importantly, TLS were also detected in tumors not directly injected, indicating that the immune response triggered by 2141-V11 is systemic in its affect, allowing immune cells to migrate and target cancer cells throughout the body.
Expanding the Horizon: Ongoing Clinical Trials & Future Directions
The promising results of the Phase 1 trial have spurred a wave of further investigation. The Ravetch lab is collaborating with researchers at Memorial Sloan Kettering and Duke university on multiple clinical trials (currently in Phase 1 or Phase 2) evaluating 2141-V11’s efficacy against a broader range of aggressive cancers, including bladder cancer, prostate cancer, and glioblastoma. These trials currently involve nearly 200 patients.
These expanded studies are designed to identify biomarkers that predict response to
![Tuesday News: Latest Updates & Headlines – [Date]](https://assets.thelocal.com/cdn-cgi/rs:fit:1200/quality:75/plain/https://apiwp.thelocal.com/wp-content/uploads/2025/12/watermarks-logo-low-angle-tQAOPzmAFfc-unsplash.jpeg@webp "Tuesday News: Latest Updates & Headlines – [Date]"){kind=logo}
